The Biotech Beat: 8.26-9.1.24
by Joey Bose and Aruesha Srivastava
🌟Upshot
In a rapidly evolving landscape of biotech and pharmaceuticals, industry giants and innovative startups alike are making bold moves to secure their future. 🎯 Johnson & Johnson seeks FDA approval for nipocalimab to challenge established players in the myasthenia gravis market, while Neurocrine faces mixed results with its schizophrenia drug NBI-1117568 in Phase 2 trials. 💉 Eli Lilly launches low-dose Zepbound vials through direct-to-consumer channels to address supply issues, as Express Scripts shifts away from Humira to embrace cost-effective biosimilars. 🧬 Pfizer partners with Quotient Therapeutics to explore somatic mutations, a novel approach in drug discovery, and Bayer bets $547M on NextRNA's lncRNA-targeting cancer therapies. 📈 Meanwhile, Indiana Biotech MBX files for an IPO, signaling a mini-revival in Nasdaq listings, and Rightway challenges traditional PBMs with its transparent model, gaining traction among major employers like TikTok and Tyson Foods. 💊 The impact of the Inflation Reduction Act on biosimilar adoption remains modest, but the coming years will be pivotal as competition intensifies, particularly with the looming arrival of biosimilars for blockbuster drugs like Stelara. 🌍 Together, these developments paint a picture of an industry in flux, where innovation, competition, and strategic partnerships are driving the next wave of breakthroughs and market shifts. 🚀
🔬 Research, Development & Drug Approvals 💊
🎯 Regeneron’s First Bispecific Antibody Finally Approved in EU Despite FDA Roadblocks
The Facts
Regeneron’s bispecific antibody odronextamab, branded as Ordspono, has received conditional approval from EU regulators for treating follicular lymphoma and diffuse large B cell lymphoma after previous treatments failed. This marks Regeneron’s first bispecific antibody approval, overcoming past challenges, though the FDA rejected it earlier this year. The approval is contingent on further clinical data. In clinical trials, odronextamab showed an 80% response rate in follicular lymphoma, with 73% achieving complete remission. Sales are projected to reach $800 million by 2035.
Our Opinion
Regeneron’s entry into the bispecific antibody market with Ordspono is a significant milestone, yet it highlights the complexities of bringing such advanced therapies to market. The EU’s approval amidst the FDA’s hesitations underscores the ongoing challenges in aligning global regulatory standards. While the clinical efficacy, particularly in follicular lymphoma, is impressive, the safety concerns and the FDA’s previous rejections could hinder broader acceptance. This case reflects the increasingly competitive and regulated environment of oncology therapeutics, where innovation must be matched with impeccable execution and data robustness.
Your Turn
Given the divergence in approval between the EU and the FDA, how should biotech companies navigate differing global regulatory landscapes when introducing innovative therapies like bispecific antibodies?
🧠 Alzheimer’s Breakthrough: Cancer Drug Shows Promise in Fighting Dementia
The Facts
A new study from Stanford University suggests that drugs designed to fight cancer could also combat Alzheimer’s disease. Researchers found that blocking the enzyme IDO1, known for its role in immune suppression in cancer, improved brain metabolism and memory in mice. The study, published in Science, shows that IDO1 inhibitors, once considered for cancer treatment, may have potential in Alzheimer's by preventing glucose metabolism disruption in brain cells. Pfizer’s experimental drug PF068 restored metabolism and memory impairments in mice, with hopes for future clinical trials.
Our Opinion
This discovery opens up a promising new avenue in Alzheimer’s research, but it’s not without its challenges. The potential repurposing of cancer drugs for neurodegenerative diseases like Alzheimer’s could revolutionize treatment approaches, especially given the lack of effective therapies currently available. However, the historical failure of amyloid and tau-targeting drugs in clinical settings raises valid concerns about translating these findings from mice to humans. The enthusiasm surrounding this study is warranted, but caution is needed as the leap from preclinical success to human efficacy remains a significant hurdle.
Your Turn
Considering the challenges in crossing the blood-brain barrier and past failures in Alzheimer’s drug development, what strategies should researchers prioritize to ensure the successful translation of these preclinical findings into effective human therapies?
🔬 FDA Greenlights Illumina’s Cancer Test: A Boon for Precision Medicine
The Facts
The FDA has approved Illumina’s TruSight Oncology Comprehensive test, which screens over 500 genes in tumors to match patients with targeted therapies. This test is particularly significant for identifying patients who may benefit from Bayer’s Vitrakvi and Eli Lilly’s Retevmo, targeting specific gene fusions and mutations in cancers. The approval enables the test's commercialization and reimbursement under Medicare and Medicaid, expanding Illumina's reach into the clinical space, following its earlier clearance in Europe.
Our Opinion
Illumina’s FDA approval marks a pivotal moment in the evolution of precision medicine, particularly in oncology. This move underscores the growing importance of companion diagnostics in tailoring treatments to individual genetic profiles, offering hope for more effective cancer therapies. However, the competitive landscape, with similar tests already on the market, and Illumina’s recent divestment of Grail, raises questions about the company’s long-term strategy in the clinical diagnostics space. While the approval is a win for Illumina, sustaining momentum in this highly competitive field will require continuous innovation and strategic clarity.
Your Turn
With the increasing competition in the companion diagnostics market, how should Illumina differentiate its offerings to ensure long-term success, particularly in the face of challenges like its recent divestment of Grail?
💉 FDA Approves First Automated Insulin Pump for Type 2 Diabetes: A Game-Changer for Millions
The Facts
The FDA has cleared Insulet’s Omnipod 5, the first automated insulin pump approved for adults with Type 2 diabetes, potentially impacting over 6 million people. This includes about 2.5 million who require multiple daily insulin injections. The Omnipod 5 system, already used by those with Type 1 diabetes, connects with continuous glucose monitors to automatically adjust insulin doses. In clinical trials, the device lowered HbA1c by 0.8 percentage points overall and by 2.1 points for those starting with levels above 9%, also increasing time spent in healthy glucose ranges by 20%.
Our Opinion
The FDA’s approval of Insulet’s Omnipod 5 for Type 2 diabetes marks a significant milestone in diabetes management, especially for a population that has seen limited progress in blood sugar control. While the technology promises to improve outcomes, the broader adoption of automated insulin delivery systems will likely hinge on factors such as cost, insurance coverage, and patient adherence. Moreover, the introduction of this device may intensify competition in the diabetes care market, pressuring companies to innovate further. However, the real test will be whether this technology can deliver sustained improvements in a diverse patient population with varying levels of diabetes severity.
Your Turn
With the increasing availability of advanced diabetes management technologies like Omnipod 5, what steps should healthcare systems take to ensure equitable access and affordability, particularly for underserved populations who may benefit the most from these innovations?
🚨 Neurocrine’s Schizophrenia Trial Hits Mixed Results: Promising Low Dose, But Major Setbacks Elsewhere
The Facts
Neurocrine Biosciences reported mixed results from its Phase 2 schizophrenia trial. The company’s drug, NBI-1117568, showed a statistically significant 7.5-point improvement over placebo on the PANSS scale at the lowest 20 mg dose, with fewer gastrointestinal side effects compared to Bristol Myers Squibb’s KarXT. However, higher doses of the drug failed to demonstrate efficacy, with placebo-adjusted PANSS reductions ranging from 1.9 to 5.0 points. Despite these setbacks, Neurocrine plans to advance the 20 mg dose into a Phase 3 study, hoping for more success with this dosage.
Our Opinion
Neurocrine’s trial results present a classic case of mixed signals in drug development. While the 20 mg dose shows promise, the failure of higher doses to deliver efficacy raises serious questions about the drug’s overall potential. The modest improvement on the PANSS scale, coupled with the lack of dose-response, suggests that while NBI-1117568 might offer a safer alternative to competitors, its effectiveness might be limited. Neurocrine’s decision to push forward with a Phase 3 trial based on these results could be a gamble, as the success of the drug now hinges on whether the low-dose results can be consistently replicated.
Your Turn
Considering the lack of dose-response and mixed efficacy results, what strategies should Neurocrine consider in their Phase 3 trial to enhance the likelihood of success, and how might these strategies differ from those used by their competitors like Bristol Myers Squibb?
🩺 Novartis' Leqvio Targets Cholesterol Blockbuster Status with New Phase 3 Data
The Facts
Novartis is pushing forward with its cholesterol-lowering drug, Leqvio, which has shown statistically significant reductions in LDL-C levels as a monotherapy in Phase 3 trials. The V-MONO study demonstrated that Leqvio, administered twice yearly, outperformed both placebo and Merck’s Zetia in patients at low or moderate risk of ASCVD who were not on other lipid-lowering therapies. This new evidence supports broader use of Leqvio, as the company continues to explore its potential across various cardiovascular treatment settings, with further results expected through 2027.
Our Opinion
Novartis' strategic push to position Leqvio as a blockbuster drug in the cholesterol management market is ambitious but comes with notable challenges. While the Phase 3 results are promising, especially as a monotherapy in patients with lower risk, the broader adoption of Leqvio will depend on overcoming the entrenched preference for statins and the perceived high cost of siRNA therapies. Additionally, the twice-yearly dosing offers a convenience advantage, but whether this translates into significant market share remains uncertain, especially in a highly competitive landscape. Novartis must navigate these hurdles effectively to achieve its blockbuster aspirations for Leqvio.
Your Turn
Given the competitive landscape of cholesterol-lowering therapies, what strategies should Novartis employ to position Leqvio favorably against established statin treatments, particularly in markets where cost and compliance are critical factors?
🎯 J&J’s Nipocalimab Takes Aim at Myasthenia Gravis Market, but Faces Fierce Competition
The Facts
Johnson & Johnson has filed for FDA approval of nipocalimab, an FcRn blocker, to treat generalized myasthenia gravis (gMG), aiming to challenge existing treatments by argenx and UCB. Acquired in the $6.5 billion takeover of Momenta Pharmaceuticals, nipocalimab is expected to generate peak sales exceeding $5 billion, despite competitors like Vyvgart and Rystiggo already being on the market. J&J highlights nipocalimab’s unique sustained disease control and broad patient coverage as differentiators, though it enters the market years behind its rivals.
Our Opinion
J&J’s entry into the gMG market with nipocalimab is a bold move, but the company faces significant challenges in overcoming the first-mover advantage of argenx and UCB. While J&J touts the drug's sustained efficacy and broader patient population, the late entry may limit its market penetration, particularly given the established positions of Vyvgart and Rystiggo. Moreover, with all three companies vying to expand their FcRn inhibitors into multiple indications, J&J will need to leverage its strengths aggressively to carve out a meaningful share in a highly competitive landscape.
Your Turn
Given the crowded market for FcRn blockers in treating gMG, what strategies should J&J employ to differentiate nipocalimab and capture market share, especially considering the established presence of argenx and UCB?
🤖 AI Fails to Impress in Biotech: Leash Bio's Competition Exposes Weakness in Predictive Modeling
The Facts
Recursion Pharmaceuticals is preparing for a pivotal 18 months, with 10 planned Phase 2 trial readouts that will determine its future in the biotech industry. Despite its heavy emphasis on AI-driven drug discovery, the company's first Phase 2 readout involves a drug, REC-994, developed using traditional methods. The success of these trials is critical, as Recursion’s valuation and survival hinge on positive outcomes, with the company facing significant financial and technological pressures. CEO Chris Gibson’s strategic financial maneuvers have kept the company afloat, but failure in these trials could severely damage Recursion’s standing in the biotech world.
Our Opinion
Recursion’s reliance on AI to drive its drug discovery process has been a key part of its narrative, but the upcoming Phase 2 readouts will test whether this AI-driven approach can deliver tangible results. The fact that the company’s most advanced drug was not designed using AI technology raises questions about the real impact of AI in their pipeline. While Recursion’s financial strategies have been savvy, the biotech industry’s harsh reality is that only successful clinical outcomes will validate its approach. Failure could not only undermine Recursion's position but also cast doubt on the broader AI-driven drug discovery field.
Your Turn
With Recursion’s upcoming trial results potentially making or breaking its future, how should investors weigh the risks associated with AI-driven drug discovery, particularly when traditional methods have been the backbone of the company’s most advanced programs?
💰 Investment, M&A, and IPOs 📈
📈 Indiana Biotech MBX Files for IPO Amid Mini-Revival in Nasdaq Listings
The Facts
Indiana-based biotech startup MBX Biosciences has filed for an IPO, becoming the third clinical-stage drug developer to do so in two days. MBX, which focuses on peptide therapies for endocrine and metabolic disorders, is backed by major investors including Frazier Life Sciences and OrbiMed. The IPO follows a recent $63.5 million Series C funding round and a Phase 2 trial initiation for its lead drug, MBX 2109, aimed at treating chronic hypoparathyroidism. The company’s filing signals a potential rejuvenation in biotech IPO activity on the Nasdaq, with market eyes turning to MBX and others to gauge investor interest.
Recommended by LinkedIn
Our Opinion
MBX Biosciences' decision to file for an IPO in a currently sluggish market is a calculated risk that could pay off if investor sentiment improves, particularly with potential federal interest rate cuts on the horizon. The startup’s focus on peptide therapies in the hotly contested endocrine and metabolic disorder space, especially with an experienced CEO like Kent Hawryluk at the helm, positions it well for attracting investor interest. However, the company will need to demonstrate strong clinical progress and leverage its recent funding to differentiate itself in a crowded market. The success of this IPO could signal a broader revival in biotech listings, but only if MBX can deliver compelling data and a clear path to market.
Your Turn
Given the recent resurgence in biotech IPOs and the specific focus of MBX Biosciences on peptide therapies for metabolic disorders, how should investors assess the risks and opportunities in this sector, especially in light of the broader market conditions and potential federal interest rate changes?
💸 UCB Offloads Chinese Neurology and Allergy Portfolio in $680M Deal with Mubadala and CBC
The Facts
Belgian pharma UCB is selling parts of its China business, including its neurology and allergy portfolio, to Abu Dhabi’s Mubadala and CBC Group for $680 million. The deal includes UCB’s mature products like Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, as well as a manufacturing site in Zhuhai. These products generated €131 million ($141 million) in China in 2023. The divestment aligns with UCB's strategy to focus more on innovation and partnerships in China, with plans to launch new medicines in immunology, neurology, and rare diseases.
Our Opinion
UCB’s strategic divestment of its mature product portfolio in China is a calculated move to pivot towards more innovative therapies in a rapidly evolving market. While the sale provides a significant cash influx, the company’s shift away from established revenue streams like Keppra and Zyrtec suggests a high-stakes bet on future product launches and partnerships. For Mubadala and CBC, this acquisition offers a strong foothold in China’s CNS market, but the challenge will be integrating these mature assets into a cohesive, growth-oriented platform amid stiff competition.
Your Turn
With UCB focusing on innovative therapies and partnerships in China, how should the company balance the risks of divesting profitable mature products with the potential rewards of launching new treatments in a competitive market?
📊 EcoR1 Takes Control Stake in Galapagos, Pressuring Biotech for Strategic Shift
The Facts
Investment fund EcoR1 Capital has increased its stake in Belgian biotech Galapagos to just under 10% and is now seeking to influence the company's strategy and governance. EcoR1 has stated that Galapagos’ shares are “deeply undervalued” and plans to engage with the company’s management and board on topics such as performance, strategic opportunities, and board composition. Galapagos' shares rose 11% on the news, but the stock remains significantly lower than its 2020 highs. The biotech, which faced setbacks including an FDA rejection for its JAK1 inhibitor, is now focused on developing a TYK2 inhibitor and a CD19-directed CAR-T therapy.
Our Opinion
EcoR1’s move to exert influence over Galapagos represents a critical juncture for the biotech, which has struggled to regain investor confidence after a series of high-profile setbacks. While the capital infusion and strategic guidance from a focused investor like EcoR1 could revitalize the company, there’s also a risk that external pressure might lead to short-term decisions that could jeopardize long-term innovation. Galapagos must carefully balance immediate shareholder demands with its broader vision for sustained growth and pipeline development.
Your Turn
With EcoR1 pushing for strategic changes at Galapagos, how should the biotech balance investor demands for immediate performance improvements with the need to invest in long-term R&D and pipeline growth, especially in a volatile biotech market?
🧬 Pfizer and Flagship’s Quotient Team Up to Explore Somatic Mutations for Novel Therapies
The Facts
Pfizer has entered a partnership with Flagship Pioneering startup Quotient Therapeutics to investigate somatic mutations—genetic mutations that arise throughout life—in order to develop new therapies for cardiovascular and renal diseases. This approach differs from traditional genomics, which focuses on inherited mutations. Quotient, which launched with $50 million from Flagship, is exploring over 30 diseases, leveraging the partnership to expand its pipeline into cardiovascular disease. This collaboration is part of a broader effort between Pfizer and Flagship, aimed at developing up to 10 therapies, with potential milestones of $700 million per successful drug.
The partnership between Pfizer and Quotient Therapeutics marks a bold step into uncharted territory in genomics. By focusing on somatic mutations, Quotient is not just pushing the boundaries of genetic research but also setting the stage for potentially groundbreaking therapies across a wide array of diseases. However, the ambitious scope of the project, especially for a small startup, raises questions about execution and resource allocation. The collaboration’s success will hinge on whether Quotient can effectively translate these genetic insights into viable therapeutic targets, particularly in the highly competitive and resource-intensive cardiovascular and renal disease markets.
Your Turn
With the growing focus on somatic mutations in drug development, how should biotech companies balance the potential for groundbreaking discoveries with the practical challenges of translating early-stage research into successful clinical therapies, especially in competitive markets like cardiovascular and renal diseases?
🧠 Bayer Bets Big on Noncoding RNA with $547M NextRNA Deal for Cancer Therapies
The Facts
Bayer has signed a partnership deal worth up to $547 million with NextRNA Therapeutics to develop cancer therapies targeting long noncoding RNAs (lncRNAs). The collaboration will focus on oncology areas with high unmet needs, with NextRNA set to receive upfront, milestone payments, and tiered royalties if the programs succeed. One of the programs is already in early preclinical development, and Bayer will select another target from NextRNA’s platform. This deal reflects Bayer’s commitment to innovative oncology research, despite the company’s ongoing restructuring efforts.
Our Opinion
Bayer's strategic move into the emerging field of lncRNA-targeting therapies underscores the company's dedication to maintaining its position as a leader in oncology, even amid significant internal restructuring. The collaboration with NextRNA Therapeutics represents a high-stakes bet on the potential of noncoding RNAs to unlock new therapeutic avenues in cancer treatment. However, the novelty of this approach also brings considerable risks, as the science behind lncRNAs is still in its early stages. Bayer's ability to navigate these uncertainties will be crucial in determining whether this partnership can deliver on its ambitious promises.
Your Turn
With Bayer investing heavily in lncRNA-targeting cancer therapies, how should the company balance the innovative potential of these emerging technologies with the inherent risks of venturing into relatively uncharted scientific territory?
⚖️ Politics & Policy 🏛️
🔄 Express Scripts Drops Humira from Formularies, Paving the Way for Biosimilars
The Facts
Cigna’s pharmacy benefit manager, Express Scripts, announced it will remove Humira from its largest commercial drug formularies in 2025 to prioritize biosimilars. This follows a similar move by CVS Caremark earlier in the year. The decision allows for greater market share for biosimilars, including those produced by Cigna’s Quallent, Boehringer Ingelheim, Teva, and Sandoz. This shift marks a significant moment in the transition from brand-name biologics to biosimilars, promising increased savings and access to upcoming blockbuster drugs.
Our Opinion
The removal of Humira from Express Scripts' formularies marks a turning point in the pharmaceutical landscape, as biosimilars finally gain a foothold in a market long dominated by AbbVie's blockbuster. This move not only signals a broader industry shift towards cost-effective alternatives but also underscores the growing pressure on brand-name biologics to compete with lower-priced biosimilars. While this could lead to substantial savings for consumers and payers, the challenge will be ensuring that the biosimilars meet the same efficacy and safety standards as their branded counterparts, maintaining trust and adherence among patients.
Your Turn
As major PBMs like Express Scripts and CVS Caremark shift towards biosimilars, how should pharmaceutical companies adapt their strategies to compete in a market increasingly focused on cost-effectiveness, without compromising on innovation and patient care?
💉 Eli Lilly Launches Low-Dose Zepbound Vials, Targeting Direct-to-Consumer Market Amid Supply Issues
The Facts
Eli Lilly is introducing low-dose vials of its obesity drug Zepbound, available exclusively through its direct-to-consumer platform LillyDirect. The 2.5-mg vials will cost $399 per month, and 5-mg vials will be $549, offering a discount compared to injectable pens. This move aims to alleviate supply constraints and attract more patients, although it could also shift patients away from compounding pharmacies. The decision reflects a broader trend in pharma towards direct-to-consumer sales, raising concerns about overprescribing and patient costs.
Our Opinion
Eli Lilly’s introduction of low-dose Zepbound vials through its direct-to-consumer platform is a strategic move to both expand market reach and address ongoing supply challenges. While this approach may enhance accessibility and control over the distribution of Zepbound, it also raises significant concerns. The shift towards direct sales channels, while potentially lucrative, risks overcommercializing patient care, with the potential for overprescribing and increased financial burden on patients, especially those without insurance coverage. Lilly's focus on the direct-to-consumer model could reshape the pharmaceutical landscape, but it must tread carefully to maintain patient trust and avoid exacerbating issues of affordability and accessibility.
Your Turn
As pharmaceutical companies like Eli Lilly increasingly shift towards direct-to-consumer sales models, how should they balance the potential for increased accessibility with the risks of overprescribing and heightened patient costs, particularly for those without comprehensive insurance coverage?
🔥 Mark Cuban’s Cost Plus Drugs Takes Aim at PBMs, Promises to Disrupt U.S. Healthcare
The Facts
Rightway, a transparent pharmacy benefit manager (PBM), is gaining traction in a market dominated by giants like CVS Caremark, Express Scripts, and OptumRx. The company, which raised $109 million this spring, has won contracts with major companies including TikTok, Zoom, and Tyson Foods. Rightway distinguishes itself by passing all discounts and savings to its customers, in contrast to traditional PBMs' secretive practices. Rightway currently serves over two million members and aims to double its membership by the end of the year, capitalizing on growing employer frustration with rising pharmacy costs and a lack of transparency.
Our Opinion
Rightway’s rapid growth and transparent business model represent a significant challenge to the entrenched dominance of traditional PBMs. As employers and health plans increasingly seek alternatives that offer greater visibility into drug pricing, Rightway’s approach could disrupt the opaque practices that have long characterized the PBM industry. However, the company faces steep competition from industry giants who are unlikely to cede market share without a fight. The success of Rightway will depend on its ability to maintain transparency while scaling its operations, proving that a more open and fair approach to managing pharmacy benefits can be both profitable and sustainable.
Your Turn
With the rise of transparent PBMs like Rightway, how should traditional PBMs respond to increasing demands for transparency and lower costs, and what impact could this shift have on the overall healthcare landscape in the U.S.?
💊 Medicare Drug Price Negotiations Slash Costs by $6 Billion, But Critics Question Long-Term Impact
The Facts
Two years after the Inflation Reduction Act (IRA) was passed, the Medicare provision offering a 2% reimbursement boost for biosimilars has had a limited impact on their adoption. A report by Certara, surveying oncology staff at 79 healthcare facilities, found that while there was some increase in biosimilar use, the overall effect has been modest. The report noted that 45% of respondents saw only a “slight increase” in biosimilar utilization due to the IRA, though most believe usage will grow over the next five years. The policy’s success will depend on its ability to overcome financial incentives favoring original biologics.
Our Opinion
The Medicare reimbursement boost for biosimilars under the IRA was designed to stimulate competition and reduce healthcare costs, but its impact so far has been underwhelming. While the policy has led to some savings, the deep-rooted financial incentives that favor originator products over biosimilars remain a significant barrier. As the healthcare industry watches for further developments, the next few years will be crucial in determining whether this policy can truly shift the market towards cost-effective alternatives, or if it will be yet another well-intentioned measure that falls short of its goals.
Your Turn
With the modest impact of the IRA’s biosimilar reimbursement provision so far, what additional policy measures or industry changes are needed to fully realize the potential cost savings that biosimilars promise, particularly in the context of upcoming biosimilar competition for blockbuster drugs like Stelara?
Disclaimer: The contents of this article are not to be construed with investment advice. The information presented in this article is a compilation of current events, technical analyses, corporate press releases, and the author's personal viewpoints about the biotechnology industry. While efforts have been made to provide accurate and timely information, there may be inadvertent errors, omissions, or inaccuracies. Therefore, investment decisions should not be made solely based on the content of this article. The article may contain statements that are forward-looking in nature, encompassing predictions and future expectations that are subject to inherent risks and uncertainties; as such, actual outcomes may significantly deviate from those expressed or implied herein. This article serves purely as an informational and entertainment resource, and should not be construed as an endorsement to purchase or sell any financial securities. Prior to engaging in any investment activities, it is imperative that you conduct comprehensive due diligence and consult with a qualified financial advisor.